August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium. TCT has chosen 20 studies that will impact the care of patients and how physicians think about cardiovascular disease. TCT, a premier educational meeting specializing in interventional cardiovascular medicine, will take place Oct. 11-15, 2015, in San Francisco, Calif.
Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that are currently or soon to be available to patients. The studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, the leading cause of death in the world. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Monday, Oct. 12; Tuesday, Oct. 13; Wednesday, Oct. 14; and Thursday, Oct. 15.
Monday, October 12:
• ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease. Presented by Dean J. Kereiakes
• ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs., an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease. Presented by Run-Lin Gao
• A Prospective Randomized Trial of Transradial vs. Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention. Presented by Shigeru Saito
• ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease – Two-Year Outcomes. Presented by Bernard R. Chevalier
• BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold – Six-Month Clinical, Angiographic and Imaging Outcomes. Presented by Michael Haude
Tuesday, Oct. 13:
• RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention. Presented by Giora Weisz
• EXPLORE: A Prospective Randomized Trial of Chronic Total Occlusion Intervention Versus Medical Therapy After Successful Primary Angioplasty in Patients With ST-Segment Elevation Myocardial Infarction. Presented by Jose P.S. Henriques
• TOTAL: A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction — One-Year Outcomes. Presented by Sanjit S. Jolly
• A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset. Presented by Steffen Desch
• PLATFORM: Quality-of-Life and Economic Outcomes of an FFR-CT Diagnostic Strategy in Patients With Suspected Coronary Artery Disease. Presented by Mark Andrew Hlatky
Wednesday, Oct. 14:
• LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding. Presented by Philip M. Urban
• TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease. Presented by Upendra Kaul
• PANDA III: A Prospective Randomized Trial of two Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics. Presented by Xu Bo
• ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis. Presented by Robert A. Byrne
• IN.PACT SFA: A Prospective Randomized Trial of a Drug-Coated Balloon for Femoropopliteal Lesions – Two-Year Outcomes. Presented by John R. Laird Jr.
Thursday, Oct. 15:
• BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement. Presented by Thierry Lefevre
• SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year Outcomes. Presented by Howard C. Herrmann
• RESPECT: A Prospective Randomized Trial of PFO Closure In Patients With Cryptogenic Stroke – Long-Term Results. Presented by John D. Carroll
• Evaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis. Presented by Tomohiko Taniguchi
• PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves. Presented by John G. Webb
The complete agenda for TCT 2015 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations and faculty on the TCT Web site.
TCT is the annual scientific symposium of CRF. The educational meeting specializes in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.
For more information: www.crf.org, www.tctconference.com
October 16, 2024 
